NorthStar Medical Radioisotopes, LLC
We are innovators who revolutionized the reliable production of Mo-99. We are dedicated to preserving the environment using non-uranium production methods. We are pioneers working with industry leaders to develop and commercialize new diagnostics and therapeutics that will serve the next generation of medical advances for patients. We are more than a radioisotope supplier. We are solving the challenges facing U.S. radioisotope customers and constantly evolving to meet changing needs. Our executive team brings proven experience and expertise in developing and commercializing innovative nuclear medicine products and technologies. NorthStar Medical Radioisotopes is poised to become the first-in-class supply chain for the future of therapeutic radiopharmaceuticals.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
NorthStar Medical Radioisotopes is poised to become the first-in-class supply chain for the future of therapeutic radiopharmaceuticals. Check back for progress on our non-carrier-added (n.c.a) Ac-225 and Cu-67 development programs.
Radioisotopes that decay by beta-particle (negatively charged electrons) or alpha-particle (helium nuclei) emissions are selected for these radiotherapeutics as they can deliver lethal radiation to tumor sites during their radioactive decay. The molecular carriers, such as monoclonal antibodies or peptides, target a specific site on a tumor cell and are designed for high tumor uptake. The radioisotopes are bound to the carrier molecules with a chemical linker to ensure the radionuclide remains attached to the molecule in the bloodstream and is carried to the tumor site to deliver their therapeutic dose. The graphic below demonstrates this process.